Hepatitis A - Pipeline Review, H1 2012 - Latest Report

Reportstack, provider of premium market research reports announces the addition of 'Hepatitis A - Pipeline Review, H1 2012' report to its offering.

The 'Hepatitis A - Pipeline Review, H1 2012', provides an overview of the Hepatitis A therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis A, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis A. 'Hepatitis A - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatitis A.
- A review of the Hepatitis A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hepatitis A pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hepatitis A.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hepatitis A pipeline depth and focus of Hepatitis A therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

To view the detailed table of contents kindly visit: http://www.reportstack.com/product/64668/hepatitis-a-pipeline-review-h1-2012.html